Illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program

Illumina Honored to Provide Technology for Arrays and Next Generation
Sequencing for Historic Research Initiative

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced the launch of its new
high-density genotyping array, the Infinium™ Global Diversity Array.
This new array was developed for and inspired by the All
of Us
Research Program
. The All of Us Research
Program is a historic effort to gather data from one million or more
people living in the United States, to accelerate human disease research
and improve health. The All of Us Research Program
is one of the country’s most ambitious biomedical research efforts ever
undertaken. It aims to build a nationwide community of at least one
million participants from all walks of life, including groups that have
been historically underrepresented in research.

In September, the All of Us Research Program awarded
funds totaling $28.6 million to three genome centers
around the
country. These centers will generate genomic data from biosamples
contributed by the program’s participants. Ultimately, this information
will become a critical component in the program’s precision medicine
research platform, a national resource to support studies on a variety
of important health questions. The All of Us Research Program is
funded and led by the National Institutes of Health (NIH), part of the
U.S. Department of Health and Human Services.

Recognizing the significant impact that this project will have on the
future of healthcare, Illumina is making a scientific contribution to
the program by providing the new Infinium™ Global Diversity Array to
process up to 1 million samples to the three genome centers, at no
charge. The new array will be a high-density chip that has been designed
to enable achievement of the primary genotyping-based goals of the
project. Those goals are unparalleled coverage of a highly diverse
cohort and the ability to return results to participants such as those
indicated by the ACMG-59
Gene List
and key pharmacogenomic variants. Some of these genes are
associated with potentially life-threatening health conditions, ranging
from familial hypercholesterolemia, to breast and ovarian cancer. The
array will become commercially available for others to use in mid-2019.

A core value of the All of Us Research Program is to
reflect the rich diversity of the United States. Including people who
have been underrepresented in biomedical research will help researchers
understand existing health disparities and ensure that everyone can
benefit from future breakthroughs,” commented Eric Dishman.

In addition to the new genotyping array, the awarded genome centers will
employ Illumina’s NovaSeq
6000 Sequencing Platform
to conduct the whole genome sequencing for
the All of Us Research Program.

This contribution to the selected All of Us Genome Centers
will allow the program to accelerate the unprecedented effort to
complete genotyping and sequencing for all 1 million or more people who
participate in the program,” said NIH Director Francis S. Collins, M.D.,
Ph.D.

We are privileged to make this scientific contribution to the All of
Us
Research Program Genome Centers,” shared Francis deSouza,
President and Chief Executive Officer of Illumina. “This landmark
initiative will build awareness of the unprecedented benefits that DNA
sequencing can have on improving the human condition. It is an
innovative program that will contribute to driving down the cost of
sequencing, while further unlocking the power of the human genome.”

About Illumina

Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com
and follow @illumina.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and
uncertainties. These forward-looking statements are based on our
expectations as of the date of this release and may differ materially
from actual future events or results. Among the important factors that
could cause actual results to differ materially from those in any
forward-looking statements are (i) our ability to further develop and
commercialize our instruments and consumables, including our diagnostic
kit products, and to deploy new products such as the MiSeq™Dx System,
services and applications, and expand the markets for our technology
platforms; (ii) our ability to manufacture robust instrumentation and
consumables; (iii) our ability to successfully identify and integrate
acquired technologies, products or businesses; (iv) the future conduct
and growth of the business and the markets in which we operate; and (v)
challenges inherent in developing, manufacturing, and launching new
products and services, together with other factors detailed in our
filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We undertake no obligation, and do not intend, to update
these forward-looking statements, to review or confirm analysts’
expectations, or to provide interim reports or updates on the progress
of the current quarter.

Contacts

Illumina, Inc.
Media Contacts
Melinda Hutcheon
(858)
882-6822
pr@illumina.com
or
Investors:
Jacquie
Ross, CFA
(858) 882-2172
ir@illumina.com